Tomohiro Tanaka

Tomohiro Tanaka

Auto-generated profile, based on publicly available information

Tomohiro Tanaka

Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
RORyuji Ohue-Kitano
Ryuji Ohue-Kitano
HNHazuki Nonaka
Hazuki Nonaka
ANAkari Nishida
Akari Nishida
YMYuki Masujima
Yuki Masujima
DTDaisuke Takahashi
Daisuke Takahashi
IKIkuo Kimura
Ikuo Kimura
Medium-chain triglycerides (MCTs), which consist of medium-chain fatty acids (MCFAs), are unique forms of dietary fat with various health benefits. G protein–coupled 84 (GPR84) acts as a receptor for MCFAs (especially C10:0 and C12:0); however, GPR84 is still considered an orphan receptor, and the nutritional signaling of endogenous and dietary MCFAs via GPR84 remains unclear. Here, we showed that endogenous MCFA-mediated GPR84 signaling protected hepatic functions from diet-induced lipotoxicity. Under high-fat diet (HFD) conditions, GPR84-deficient mice exhibited nonalcoholic steatohepatitis (NASH) and the progression of hepatic fibrosis but not steatosis. With markedly increased hepatic MCFA levels under HFD, GPR84 suppressed lipotoxicity-induced macrophage overactivation. Thus, GPR84 is an immunomodulating receptor that suppresses excessive dietary fat intake–induced toxicity by sensing increases in MCFAs. Additionally, administering MCTs, MCFAs (C10:0 or C12:0, but not C8:0), or GPR84 agonists effectively improved NASH in mouse models. Therefore, exogenous GPR84 stimulation is a potential strategy for treating NASH.

1 April 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
KOKento Ogawa
Kento Ogawa
TYTakashi Yagi
Takashi Yagi
TGTingting Guo
Tingting Guo
KTKatsushi Takeda
Katsushi Takeda
HOHideomi Ohguchi
Hideomi Ohguchi
TTTomohiro Tanaka
Tomohiro Tanaka

22 February 2023 in Clinical Transplantation
Verified
Journal Article
Closed access
KLKrista L Lentine
Krista L Lentine
TTTomohiro Tanaka
Tomohiro Tanaka
HXHuiling Xiao
Huiling Xiao
TBTherese Bittermann
Therese Bittermann
MDMary Amanda Dew
Mary Amanda Dew
DADavid A. Axelrod
David A. Axelrod

23 January 2018 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
TTTomohiro Tanaka
Tomohiro Tanaka
MVMichael D. Voigt
Michael D. Voigt

15 March 2020 in Internal Medicine
Verified
Journal Article
Open access
PDF file
HKHiroyuki Koyama
Hiroyuki Koyama
SYSatoshi Yasuda
Satoshi Yasuda
SKShota Kakoi
Shota Kakoi
YOYasuhisa Ohata
Yasuhisa Ohata
YSYuki Shimizu
Yuki Shimizu
TTTomohiro Tanaka
Tomohiro Tanaka
A 40-year-old Japanese woman presented to our hospital with general fatigue and muscle weakness. She had a history of premature loss of deciduous teeth at 4 years old, her serum alkaline phosphatase (ALP) activity was as low as 91 U/L, and radiologic studies revealed thoracic deformity and sacroiliac calcification. Genetic sequencing revealed a heterozygous c.1559delT mutation in the tissue non-specific alkaline phosphatase gene (ALPL). Based on these findings, she was diagnosed with hypophosphatasia (HPP), and treatment with asfotase alfa, a recombinant human tissue-nonspecific alkaline phosphatase (TNSALP), was initiated. After six months of treatment with asfotase alfa, improvements were observed in the SF-36 score, six-minute walk distance, and grasping power. Although the overdiagnosis needs to be avoided, HPP should be considered in patients with undiagnosed musculoskeletal symptoms and a low serum ALP activity.

9 July 2026 in New England Journal of Medicine
Verified
Journal Article
Closed access
JMJennifer L Miller
Jennifer L Miller
HSHanneke M van Santen
Hanneke M van Santen
SPSusan A Phillips
Susan A Phillips
JHJill Hamilton
Jill Hamilton
JAJens Aberle
Jens Aberle
TGTRANSCEND Trial Group
TRANSCEND Trial Group
A phase 2 trial of setmelanotide, a melanocortin-4 receptor agonist, showed substantial weight loss in patients with acquired hypothalamic obesity, but additional data are needed. We conducted a phase 3 trial in which participants were randomly assigned in a 2:1 ratio to receive setmelanotide (at a dose of 1.5 to 3.0 mg) or placebo administered subcutaneously once daily for 52 weeks after a dose-escalation period. Persons at least 4 years of age were potentially eligible for the trial if they had acquired hypothalamic obesity, which was defined by a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) that was at or above the 95th percentile for age and sex (for participants <18 years of age) or at least 30 (for participants ≥18 years of age) and a history of a hypothalamic tumor, lesion, or injury. The primary end point was the mean percent change in BMI from baseline to 52 weeks after the end of the dose-escalation period. Secondary end points included the mean change in the weekly average of the maximal daily hunger score (range, 0 to 10, with higher scores indicating more severe hunger), assessed in participants at least 12 years of age. From April 26, 2023, to March 18, 2025, a total of 120 participants were assigned to receive setmelanotide (81 participants) or placebo (39 participants). The mean (±SD) age was 19.9±13.8 years (range, 4 to 66). Among participants 18 years of age or older, the mean BMI was 41.2±9.7; the mean BMI z score among those younger than 18 years of age was 3.61±1.66. The least-squares mean (LSM) change in BMI at 52 weeks was -16.5% (95% confidence interval [CI], -19.3 to -13.8) with setmelanotide and 3.3% (95% CI, -0.6 to 7.2) with placebo (P<0.001), and the LSM change in the weekly average of maximal daily hunger scores was -2.73 (95% CI, -3.28 to -2.18) in the setmelanotide group and -1.45 (95% CI, -2.23 to -0.67) in the placebo group (P = 0.009). Adverse events were reported in 100% of the participants in the setmelanotide group and in 90% of those in the placebo group, and serious adverse events were reported in 28% and 8%, respectively. The most common adverse events with setmelanotide were skin hyperpigmentation, nausea, vomiting, and headache. Setmelanotide led to significantly greater reductions in BMI and hunger than placebo at 52 weeks among participants 4 to 66 years of age with acquired hypothalamic obesity. (Funded by Rhythm Pharmaceuticals; TRANSCEND ClincialTrials.gov number, NCT05774756.).